Denali Therapeutics Inc. Forecast, price target & analysts
Denali Therapeutics Inc. Target price 2026 - Analyst rating & recommendation
Denali Therapeutics Inc. Classifications & Recommendation
Denali Therapeutics Inc. Price Target
| Target Price | $35.70 |
| Price | $20.39 |
| Potential |
75.09%
register free of charge
|
| Number of Estimates | 17 |
|
17 Analysts have issued a price target Denali Therapeutics Inc. 2027 .
The average Denali Therapeutics Inc. target price is $35.70.
This is
75.09%
register free of charge
$44.10
116.28%
register free of charge
$27.27
33.74%
register free of charge
|
|
| A rating was issued by 26 analysts: 24 Analysts recommend Denali Therapeutics Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Denali Therapeutics Inc. stock has an average upside potential 2027 of
75.09%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 39.19 |
22 Analysts have issued a sales forecast Denali Therapeutics Inc. 2026 . The average Denali Therapeutics Inc. sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Denali Therapeutics Inc. EBITDA forecast 2026. The average Denali Therapeutics Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
22 Denali Therapeutics Inc. Analysts have issued a net profit forecast 2026. The average Denali Therapeutics Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.97 | -2.47 |
| 15.56% | 16.84% | |
| P/E | negative | |
| EV/Sales | 65.17 |
22 Analysts have issued a Denali Therapeutics Inc. forecast for earnings per share. The average Denali Therapeutics Inc. EPS is
This results in the following potential growth metrics and future valuations:
Denali Therapeutics Inc....
Current Denali Therapeutics Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| UBS |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Jul 23 2026 |
| Deutsche Bank |
Locked
➜
Locked
|
Locked | Jul 16 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | May 26 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | May 14 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
UBS:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Jul 23 2026 |
|
Locked
Deutsche Bank:
Locked
➜
Locked
|
Jul 16 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
May 26 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
May 14 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
